Erica S. Tsang

Toronto, ON M5T1P5, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 54 publications

Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM).

Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM).

Journal: JCO oncology advances

Published: August 18, 2026

Salvage Radiotherapy in Isolated Locoregional Recurrence of Pancreatic Adenocarcinoma Post-Radical Surgical Resection: Prudent or Pointless? A Retrospective Comparative Analysis.

Salvage Radiotherapy in Isolated Locoregional Recurrence of Pancreatic Adenocarcinoma Post-Radical Surgical Resection: Prudent or Pointless? A Retrospective Comparative Analysis.

Journal: Current oncology (Toronto, Ont.)

Published: April 28, 2026

Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.

Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 24, 2025

PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.

PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 10, 2025

Molecular Tumor Board-Guided Targeted Treatments for Biliary Tract Cancers in a Publicly Funded Healthcare System.

Molecular Tumor Board-Guided Targeted Treatments for Biliary Tract Cancers in a Publicly Funded Healthcare System.

Journal: Current oncology (Toronto, Ont.)

Published: December 23, 2024

Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma.

Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma.

Journal: Journal of gastrointestinal cancer

Published: November 24, 2024

Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial.

Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial.

Journal: Nature communications

Published: November 20, 2024

Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies.

Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies.

Journal: JCO precision oncology

Published: November 07, 2024

Vascular Resection for Pancreas Cancer - 10-year Experience from a Single High Volume-center.

Vascular Resection for Pancreas Cancer - 10-year Experience from a Single High Volume-center.

Journal: Annals of surgery

Published: October 17, 2024

Vascular Resection for Pancreas Cancer: Ten Years Experience From a Single High-volume Center.

Vascular Resection for Pancreas Cancer: Ten Years Experience From a Single High-volume Center.

Journal: Annals of surgery

Published: October 17, 2024

Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer Care.

Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer Care.

Journal: Current oncology (Toronto, Ont.)

Published: August 22, 2024

The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer.

The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer.

Journal: NPJ precision oncology

Published: August 04, 2024

Showing 1-12 of 54

Last Updated: 09/26/2026